Stem Cell Clinic

European Commission approves Roche’s Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

By Global News Feed

Basel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladder and breast cancer.7 Until now, Tecentriq has been given directly into patients’ veins by IV infusion which takes approximately 30-60 minutes.6 The new subcutaneous injection will cut treatment time to approximately seven minutes, with most injections taking between four and eight minutes.6 The marketing authorisation applies to all approved indications of Tecentriq IV.7

More:
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Induced Pluripotent Stem Cells Global Market Report 2023-2028 – Key Market Drivers Include Use of iPSCs in … – PR Newswire

By Induced Pluripotent Stem Cells

DUBLIN, Jan. 10, 2024 /PRNewswire/ --The"Induced Pluripotent Stem Cells: Global Markets 2023-2028" report has been added toResearchAndMarkets.com's offering.

This study focuses on the market side of iPSCs rather than the technical side. Different market segments for this emerging market are covered. For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types.

Other cell types are comprised of astrocytes, fibroblasts, and hematopoietic and progenitor cells, among other substances. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications, and research publications in the field.

This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products that are broadly applicable to any stem cell type.

This report discusses key manufacturers, technologies, and factors influencing market demand, including the driving forces and limiting factors of the iPSC market's growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2028.

One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies; body-on-a-chip; and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.

Detailed technologies such as those for generating iPSCs, differentiating iPSCs and controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under Good Manufacturing Practice (GMP) compliance or xeno-free conditions are excluded from the study. They are beyond the scope of this report.

The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW). The report will provide details with respect to induced pluripotent stem cells.

The Report Includes

Companies Profiled

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Market Dynamics

Chapter 5 Induced Pluripotent Stem Cell Applications

Chapter 6 Induced Pluripotent Stem Cell Market Segmentation and Forecast

Chapter 7 Induced Pluripotent Stem Cells Research Application Market

Chapter 8 Induced Pluripotent Stem Cell Contract Service Market

Chapter 9 Clinical Application Market Trend Analysis

Chapter 10 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/i3vsaw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Read more here:
Induced Pluripotent Stem Cells Global Market Report 2023-2028 - Key Market Drivers Include Use of iPSCs in ... - PR Newswire

Global Cell Line Development Industry on Track for a US$10.6 Billion Boom by 2033, Fuelled by 7.7% CAGR | FMI … – Market Research Blog

By Stell Cell Research

In a groundbreaking revelation, the Global Cell Line Development Industry is poised for an extraordinary surge, with sales projected to reach an impressive US$10.6 billion by 2033, propelled by a robust Compound Annual Growth Rate (CAGR) of 7.7% from 2023. These findings, based on a comprehensive analysis by Future Market Insights (FMI), reveal a significant leap from the estimated US$4.7 billion valuation in 2022.

The driving force behind this unprecedented growth is the escalating adoption of bio-therapeutics for the treatment of chronic diseases such as arthritis, diabetes, and cancer. As the demand for innovative therapeutic solutions continues to rise, the Global Cell Line Development Industry is witnessing an increased need for automated cell line development and specialized cell line development services.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-7566

The rapid increase in the prevalence of cancer and neurology disorders and the lack of efficient treatment solutions for these diseases have created the need for more advanced and efficient treatment pathways. Companies and government organizations are investing in research and development activities and are also focusing more on cell line development in search of new cellular pathways to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide a boost to the Global Cell Line Development Industry.

In recent times contract research organizations have focused on cell line development and cell line research activities. According to the National Institutes of Health (NIH), the estimated total federal spending on all types of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, the government is supporting cell line development through national funding agencies like the Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the Department of Science and Technology (DST).

Regenerative medicines are the next-generation treatment solution and Cell Line Development or Cell Culture is a vital part of regenerative medicine. Increasing demand for regenerative medicines in cancer treatment would positively impact the growth of the Global Cell Line Development Industry over the forecast period.

The biopharmaceutical companies operating in the development of novel drug lines are expected to hold promising revenue opportunities in the Global Cell Line Development Industry.

Future Market Insights (FMI) has segmented the Global Cell Line Development Industry based on product type, cell line source type, end user, type of cell line, and region.

Product type segment in the Global Cell Line Development Industry is segmented into media and reagents, equipment, and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. The reagent and media segment in the cell line development market is expected to witness noteworthy growth in terms of revenue owing to a rapid increase in demand for cell culture and cell-based assays.

Global Cell Line Development Industry by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipated to witness significant growth in the overall Global Cell Line Development Industry. This growth of the mammalian cells segment in the cell line development market is driven by increased production of biologics drugs that require mammalian cells. Increasing antibody production is the major driving factor behind the growth of the mammalian cell lines segment in the Global Cell Line Development Industry.

Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gauchers disease, is a genetic disorder characterized by a lack of -glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produced in mammalian cell lines. Mammalian cell lines are also useful in the production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease-causing agents in the body. For example Under the cell line type segment in the Global Cell Line Development Industry, recombinant cell line development is the most demanding type of cell line due to its large application in biologics production, protein interaction, gene activation, toxicity testing, and drug screening.

Request Your Customized Report Now! https://www.futuremarketinsights.com/customization-available/rep-gb-7566

Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period

North American and European cell line development markets will dominate owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to the increased number of research organizations engaged in novel biologics and biosimilars fastest revenue growth in the overall cell line development market.

The Asia Pacific region in the Cell line development market is anticipated to witness increasing demand for biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.

FMIs report tracks some of the key companies operating in the Global Cell Line Development Industry, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.

Key Segments:

By Source Type:

By End User:

By Cell Lines:

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-7566

Author

Sabyasachi Ghosh(Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA T: +1-845-579-5705 For Sales Enquiries:sales@futuremarketinsights.com Website:https://www.futuremarketinsights.com LinkedIn|Twitter|Blogs|YouTube

See original here:
Global Cell Line Development Industry on Track for a US$10.6 Billion Boom by 2033, Fuelled by 7.7% CAGR | FMI ... - Market Research Blog

→←